SCHEMBL5637170

SCHEMBL5637170

FC(F)(F)c1ccccc1-c1cc2c3c(c1)[C@@H]1CNCC[C@@H]1N3CCCO2

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 11/20 0.54
HTR2B P41595 6/20 0.54
HTR2A P28223 5/20 0.54
KDM4C Q9H3R0 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
CYP2D6 P10635 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6752904 0.94 HTR2C (0.51) HTR2CHTR2BHTR2AKDM4CSLC6A2
SCHEMBL5638490 0.88 HTR2C (0.56) HTR2CHTR2BHTR2A
SCHEMBL5637064 0.88 HTR2C (0.56) HTR2CHTR2BHTR2A
SCHEMBL5636468 0.86 HTR2C (0.75) HTR2CHTR2BHTR2A
SCHEMBL5637201 0.86 HTR2C (0.56) HTR2CHTR2BHTR2A
SCHEMBL5636401 0.86 HTR2C (0.45) HTR2CHTR2BHTR2AKDM4CKCNH2
SCHEMBL5635487 0.86 HTR2C (0.45) HTR2CHTR2BHTR2AKDM4C
SCHEMBL5637404 0.84 HTR2C (0.48) HTR2CHTR2BHTR2AKCNH2
SCHEMBL5636676 0.84 HTR2C (0.44) HTR2CHTR2BHTR2A
SCHEMBL5635916 0.84 HTR2C (0.44) HTR2CHTR2BHTR2ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39679-E1 Substituted heterocycle fused gamma-carbolines BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-06-05 US disclosed
US-6713471-B1 SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-30 US disclosed